-
Mashup Score: 0Dosing Schedule for Adjuvant Chemo in High-Risk Early Breast Cancer Can Be Patient’s Choice - Oncology Nurse Advisor - 4 hour(s) ago
The selection and schedule of treatment should depend on patient preference and toxicity potential, according to Azka Ali, MD.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Analysis of Nurse Involvement in Germline BRCA Testing Pathways - Oncology Nurse Advisor - 1 day(s) ago
A study of genetic testing pathways identified roles for nurses in counseling, addressing consent, conducting blood tests, and communicating results.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
A new study describes ways in which nurses have a role in the BRCA1/BRCA2 testing process. Reported in @oncologynursing. https://t.co/64b74XoDsT
-
-
Mashup Score: 0
The prognosis of patients diagnosed with cancer after starting hemodialysis appears comparable to that of patients with cancer in the general population.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
In a study of patients diagnosed with cancer after initiating #hemodialysis, the 3-year survival rate was substantially higher among patients treated with surgery than those who were not, according to a recent report. From @renalandurology. https://t.co/3adigSbkXC… https://t.co/g9kFK6Dnhx
-
-
Mashup Score: 0Risk of Cardiac Events Higher With Osimertinib Than With Other TKIs - Oncology Nurse Advisor - 4 day(s) ago
Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Patients with EGFR-mutant non-small cell #lungcancer are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, study results suggest. From @CancerTherAdvsr. https://t.co/P9VK0hkhrV #NSCLC #lcsm
-
-
Mashup Score: 0Belzutifan Plus Cabozantinib: A First-Line Treatment for Advanced RCC? - Oncology Nurse Advisor - 5 day(s) ago
“The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in advanced clear-cell renal cell carcinoma,” researchers wrote.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
The combination of belzutifan and cabozantinib has demonstrated “promising” antitumor activity in treatment-naive patients with advanced clear-cell #renalCellCarcinoma. Reported in @TheLancetOncol and @CancerTherAdvsr. https://t.co/Y0HHZuLsCJ #RCC
-
-
Mashup Score: 0Radioiodine Therapy Unnecessary After Thyroidectomy in Low-Risk Thyroid Cancer - Oncology Nurse Advisor - 6 day(s) ago
Researchers conducted a randomized controlled trial to assess the need for postoperative radioiodine therapy among patients with low-risk thyroid cancer.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Postoperative radioiodine administration is unnecessary for patients with low-risk #thyroidcancer. Published in @TheLancetEndo and @EndoAdvisor. https://t.co/3rhl5lKPH8
-
-
Mashup Score: 0Mobile Internet-Based Postop Management Enhanced Patient Experience After Radical Prostatectomy - Oncology Nurse Advisor - 7 day(s) ago
Researchers conducted a retrospective study to determine the effectiveness of internet-based postop care for patients with prostate cancer.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Use of a mobile internet-based management approach resulted in a better postoperative experience for patients with #prostatecancer who underwent radical prostatectomy. https://t.co/eGtA4eXX4j #pcsm
-
-
Mashup Score: 0Elevated TAT Plus Other Markers Found to Be Predictive of VTE in Cervical Cancer - Oncology Nurse Advisor - 9 day(s) ago
Researchers developed an assay kit for TAT, then conducted a retrospective analysis to determine its ability to predict VTE in patients with cervical cancer.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Elevated TAT levels are a predictor for thrombosis, and incorporating TAT levels into screening of patients with #cervicalCancer showed value as a predictor of VTE in this patient population. https://t.co/plbo96C6KX #gyncsm
-
-
Mashup Score: 0Modakafusp Alfa Demonstrates Activity in Rel/Ref Multiple Myeloma - Oncology Nurse Advisor - 11 day(s) ago
Both dose levels of modakafusp alfa “resulted in good response rates with similar safety profiles,” according to researchers.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Modakafusp alfa “warrants continued exploration” as a treatment for patients with relapsed or refractory #multipleMyeloma, according to researchers. From @CancerTherAdvsr. https://t.co/x7how8mFXW
-
-
Mashup Score: 0No Change in Health-Related QoL Observed With Gilteritinib Maintenance Therapy in AML - Oncology Nurse Advisor - 11 day(s) ago
Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Although some patients with #AML who received gilteritinib maintenance therapy experienced TEAEs, there was no significant change in HRQoL measures compared with placebo. Published in @BloodAdvances and @HematologyAdv. https://t.co/ptIZIUKluN #leusm
-
Patients with high-risk early #breastcancer have similar survival outcomes with different dosing schedules of adjuvant anthracycline- and taxane-based chemotherapy. Presented at @SABCSSanAntonio #SABCS24, reported by @CancerTherAdvsr. https://t.co/oVsL61juOd #bcsm